Publications by authors named "Jacobus Lubsen"

Claim this Profile
T
The future of clinical trials in secondary prevention after acute coronary syndromes.
Héctor Bueno, Paul W Armstrong, Martin J Buxton, Nicolas Danchin, Jacobus Lubsen

Eur Heart J· July 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term impact of secondary preventive treatments in patients with stable angina.
Zoltán Vokó, Sophie de Brouwer, Jacobus Lubsen, Nicolas Danchin, Jan-Erik Otterstad

Eur J Epidemiol· May 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Statins and risk of incident diabetes.
Jacobus Lubsen

Lancet· June 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Subgroup effects despite homogeneous heterogeneity test results.
Rolf H H Groenwold, Maroeska M Rovers, Jacobus Lubsen, Geert Jmg van der Heijden

BMC Med Res Methodol· May 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gender differences in cardiac remodeling and clinical outcomes in chronic stable angina pectoris (from the ACTION Trial).
Bonnie Ky, Bridget-Anne Kirwan, Sophie de Brouwer, Jacobus Lubsen, Philip Poole-Wilson

Am J Cardiol· April 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correlates of coronary angiography in patients with stable angina and geographical differences in its utilisation: the ACTION experience.
Zoltán Vokó, Nicolas Danchin, Sophie de Brouwer, Bridget-Anne Kirwan, Philip A Poole-Wilson, Jacobus Lubsen

Int J Cardiol· January 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Commentary on 'Measurement in clinical trials: a neglected issue for statisticians?'.
Jacobus Lubsen

Stat Med· November 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Unconventional end points in cardiovascular clinical trials: should we be moving away from morbidity and mortality?
Jay Cohn, John G F Cleland, Jacobus Lubsen, Jeffrey S Borer, Philippe Gabriel Steg

J Card Fail· April 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[JUPITER study about rosuvastatin and risk of cardiovascular disease. Unclear consequences for the guideline].
Jacobus Lubsen

Ned Tijdschr Geneeskd· February 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A propensity-matched study of hypertension and increased stroke-related hospitalization in chronic heart failure.
Gerasimos S Filippatos, Chris Adamopoulos, Xuemei Sui, Thomas E Love, Patrick M Pullicino, Jacobus Lubsen

Am J Cardiol· June 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
More on subgroup analyses in clinical trials.
Stuart J Pocock, Jacobus Lubsen

N Engl J Med· May 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Meta-analyses of chronic disease trials with competing causes of death may yield biased odds ratios.
Michael T Koller, Theo Stijnen, Ewout W Steyerberg, Jacobus Lubsen

J Clin Epidemiol· April 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quality management of a large randomized double-blind multi-centre trial: the ACTION experience.
Bridget-Anne Kirwan, Jacobus Lubsen, Sophie de Brouwer, Frederik J van Dalen, Stuart J Pocock

Contemp Clin Trials· March 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Diagnostic criteria and adjudication process both determine published event-rates: the ACTION trial experience.
Bridget-Anne Kirwan, Jacobus Lubsen, Sophie de Brouwer, Nicolas Danchin, Alexander Battler

Contemp Clin Trials· November 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predictive value of local and core laboratory echocardiographic assessment of cardiac function in patients with chronic stable angina: The ACTION study.
Anthony M Dart, Jan Erik Otterstad, Bridget-Anne Kirwan, John D Parker, Sophie de Brouwer, Jacobus Lubsen

Eur J Echocardiogr· August 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical course of isolated stable angina due to coronary heart disease.
Philip A Poole-Wilson, Zoltán Vokó, Bridget-Anne Kirwan, Sophie de Brouwer, Peter H J M Dunselman, Jacobus Lubsen

Eur Heart J· August 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Uric acid and other renal function parameters in patients with stable angina pectoris participating in the ACTION trial: impact of nifedipine GITS (gastro-intestinal therapeutic system) and relation to outcome.
Luis M Ruilope, Bridget-Anne Kirwan, Sophie de Brouwer, Nicolas Danchin, Keith A A Fox, Jacobus Lubsen

J Hypertens· August 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Blood pressure reduction in stable angina by nifedipine was related to stroke and heart failure reduction but not to coronary interventions.
Jacobus Lubsen, Zoltán Vokó, Philip A Poole-Wilson, Bridget-Anne Kirwan, Sophie de Brouwer

J Clin Epidemiol· July 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Resource utilization implications of treatment were able to be assessed from appropriately reported clinical trial data.
Philip A Poole-Wilson, Bridget-Anne Kirwan, Zoltán Vokó, Sophie de Brouwer, Peter H J M Dunselman, Jacobus Lubsen

J Clin Epidemiol· July 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The development of heart failure in patients with stable angina pectoris.
George C Sutton, Jan Erik Otterstad, Bridget-Anne Kirwan, Zoltán Vokó, Sophie de Brouwer, Jacobus Lubsen

Eur J Heart Fail· March 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The DREAM trial.
Jacobus Lubsen, Philip A Poole-Wilson

Lancet· December 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Variable impact of combining fatal and nonfatal end points in heart failure trials.
Hicham Skali, Marc A Pfeffer, Jacobus Lubsen, Scott D Solomon

Circulation· November 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Incidence and outcome of atrial fibrillation in stable symptomatic coronary disease.
Jan Erik Otterstad, Bridget-Anne Kirwan, Jacobus Lubsen, Sophie De Brouwer, Keith A A Fox

Scand Cardiovasc J· June 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A comparison of the effects of carvedilol and metoprolol on well-being, morbidity, and mortality (the "patient journey") in patients with heart failure: a report from the Carvedilol Or Metoprolol European Trial (COMET).
John G F Cleland, Andrew Charlesworth, Jacobus Lubsen, Karl Swedberg, Willem J Remme

J Am Coll Cardiol· April 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety of nifedipine GITS in stable angina: the ACTION trial.
Philip A Poole-Wilson, Bridget-Anne Kirwan, Zoltán Vokó, Sophie de Brouwer, Fred J van Dalen, Jacobus Lubsen

Cardiovasc Drugs Ther· February 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis